<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="450">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05155293</url>
  </required_header>
  <id_info>
    <org_study_id>AVT06-GL-C01</org_study_id>
    <nct_id>NCT05155293</nct_id>
  </id_info>
  <brief_title>Randomized Multicener Clinical Study to Evaluate the Efficacy and Safety of AVT06 Compared With EU-Eylea (ALVOEYE)</brief_title>
  <acronym>ALVOEYE</acronym>
  <official_title>A Randomized, Double-masked, Parallel-group, Multicenter Clinical Study to Evaluate the Efficacy and Safety of AVT06 Compared With EU-Eylea® in Subjects With Neovascular (Wet) Age-related Macular Degeneration (ALVOEYE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alvotech Swiss AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alvotech Swiss AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, randomized, double-masked, parallel-group, multicenter, therapeutic&#xD;
      equivalence study evaluating the efficacy, safety, and immunogenicity of AVT06 compared with&#xD;
      Eylea in subjects with neovascular (wet) AMD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2022</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to Week 8 in Best-corrected Visual Acuity (BCVA)</measure>
    <time_frame>Week 8</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Neovascular (Wet) AMD</condition>
  <arm_group>
    <arm_group_label>AVT06 (proposed aflibercept biosimilar)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 1 IVT injection of AVT06 every 4 weeks for the first 3 consecutive doses, followed by 1 IVT injection every 8 weeks through study completion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eylea® (Aflibercept)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 1 IVT injection of Eylea® every 4 weeks for the first 3 consecutive doses, followed by 1 IVT injection every 8 weeks through study completion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AVT06 (proposed aflibercept biosimilar)</intervention_name>
    <description>Patients will receive IVT injections of AVT06</description>
    <arm_group_label>AVT06 (proposed aflibercept biosimilar)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eylea® (Aflibercept)</intervention_name>
    <description>Patients will receive IVT injections of Eylea®</description>
    <arm_group_label>Eylea® (Aflibercept)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject must be ≥50 years of age, at the time of signing the informed consent.&#xD;
&#xD;
          -  Subjects must be diagnosed with neovascular (wet) AMD in the study eye.&#xD;
&#xD;
          -  Subjects must have active, treatment naïve, subfoveal CNV lesions secondary to&#xD;
             neovascular (wet) AMD.&#xD;
&#xD;
          -  Willingness and ability to undertake all scheduled visits and assessments.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any prior systemic treatment with anti-VEGF therapy&#xD;
&#xD;
          -  Any condition that, in the Investigator ́s opinion, can interfere with full&#xD;
             participation in the study, including administration of the study treatment and&#xD;
             attending required visits; can pose a significant risk to the participant, or&#xD;
             interfere with interpretation of study data&#xD;
&#xD;
          -  Prior treatment with any investigational drugs within 30 days or 5 half-lives&#xD;
             (whichever is longer) of the previous investigational treatment before initiation of&#xD;
             the study treatment or concomitant enrollment in any other clinical study involving an&#xD;
             investigational study treatment&#xD;
&#xD;
          -  Subjects not suitable for participation, whatever the reason, as judged by the&#xD;
             Investigator, including medical or psychiatric conditions, or participants potentially&#xD;
             at risk of noncompliance to study procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 1, 2021</study_first_submitted>
  <study_first_submitted_qc>December 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2021</study_first_posted>
  <last_update_submitted>December 1, 2021</last_update_submitted>
  <last_update_submitted_qc>December 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

